Geyer, C. E., Untch, M., Huang, C., Mano, M. S., Mamounas, E. P., Wolmark, N., Rastogi, P., Schneeweiss, A., Redondo, A., Fischer, H. H., D’Hondt, V., Conlin, A. K., Guarneri, V., Wapnir, I. L., Jackisch, C., Arce-Salinas, C., Fasching, P. A., DiGiovanna, M. P., Crown, J. P., Wuelfing, P., Shao, Z., Caremoli, E. R., Bonnefoi, H. R., Hennessy, B. T., Stamatovic, L., Castro-Salguero, H., Brufsky, A. M., Knott, A., Siddiqui, A., Lambertini, C., Boulet, T., Nyawira, B., Restuccia, E., Loibl, S. (2025). Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2406070